Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | FPR2 | P25090 | 3/20 | 0.31 |
| ▸ | PROKR1 | Q8TCW9 | 3/20 | 0.31 |
| ▸ | GNRHR | P30968 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | CD74 | P04233 | 1/20 | 0.30 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20137954 | 0.84 | HTR1A (0.38) | HTTKMT2AALDH1A1 | |
| SCHEMBL20138285 | 0.82 | GALR3 (0.36) | HTTTSHRPROKR1KMT2ASMN1; SMN2 | |
| SCHEMBL20137999 | 0.81 | TSHR (0.35) | HTTTSHRLMNAKMT2ASMN1; SMN2 | |
| SCHEMBL20138097 | 0.81 | GRM2 (0.32) | GNRHRKMT2ASMN1; SMN2MAPK1 | |
| SCHEMBL20138199 | 0.80 | CYP11B2 (0.35) | HTTTSHRGNRHRLMNAKMT2A | |
| SCHEMBL18305075 | 0.77 | CYP11B2 (0.34) | HTTTSHRLMNAKMT2ASMN1; SMN2 | |
| SCHEMBL20137971 | 0.77 | SMN1; SMN2 (0.36) | HTTTSHRGNRHRLMNAKMT2A | |
| SCHEMBL20138189 | 0.73 | SMN1; SMN2 (0.34) | HTTTSHRGNRHRKMT2ASMN1; SMN2 | |
| SCHEMBL20138128 | 0.70 | SHMT2 (0.34) | SMN1; SMN2 | |
| SCHEMBL20138092 | 0.69 | SMN1; SMN2 (0.36) | LMNAKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10287299-B2 | Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activity | UCB BIOPHARMA SPRL (BE) | 2019-05-14 | — | — | US | disclosed |
| US-20180134728-A1 | Benzoxazinone Derivatives and Analogues Thereof as Modulators of TNF Activity | UCB S.A. (BE) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134728-A1 | Benzoxazinone Derivatives and Analogues Thereof as Modulators of TNF Activity | TNF, NFKBIA, TNFRSF1A | HTT 303/4885TSHR 2169/4885FPR2 1336/4885 |
| US-10287299-B2 | Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activity | TNF, TNFRSF1A, NFKBIA | HTT 3751/4885TSHR 940/4885FPR2 828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.